Chargement en cours...
QLIF-09. LONGTERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY
INTRODUCTION: Glioblastoma (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median surviva...
Enregistré dans:
| Publié dans: | Neuro Oncol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692852/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.819 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|